The Arrogance of 'Pop Science'

Now that Time Inc. has sold Discover, its prize-winning popular science magazine, no major magazine or commercial television show started during the popular science "boom" of the last decade has succeeded. What happened? And, more important to science professionals, what's going to happen? The Rise and Fall Between 1977 and 1986 nearly 20 new magazines, 17 new television shows, and more than 60 newspaper sections devoted to popular science appeared. Several of these new ventures breached the wal

Written byBruce Lewenstein
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Of these ventures, the most prominent were three magazines (Discover, Science Digest, and Science 80, later 81,82, etc.) whose finances depended on commercial advertising. Science was to be an economic commodity that could be sold in the same way that skiing, sailing or city life are sold in magazines.

Not surprisingly, the new project excited professional science writers. Vocal about their support (through articles in the trade press and elsewhere), they helped create a media bandwagon. By 1980, the boom was on.

At first, signs were good as Science 80 doubled its expected circulation (to 700,000) and as Discover regularly sold more than 750,000 copies. But disturbing problems ap peared quickly, when a few magazines, such as Technology and SciQuest, folded by 1981.

Although some observers attributed the failures to magazine economics, others questioned the viability of popular science projects—especially those, like Science 80, which were supported by scientific organizations ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies